Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 May 2024
04 May 2024
Historique:
received:
20
09
2023
accepted:
19
04
2024
revised:
12
04
2024
medline:
5
5
2024
pubmed:
5
5
2024
entrez:
4
5
2024
Statut:
aheadofprint
Résumé
Tregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in peripheral blood (PB)-Tregs isolated from primary RCC patients. PB-Tregs were isolated from 77 RCC patients and 38 healthy donors (HDs). CFSE-T effector-Tregs suppression assay, IL-35, IFN-γ, IL-10, TGF-β1 secretion, and R54 impaired PB-RCC-Tregs function, reduced R54 impairs Tregs function in primary RCC patients targeting PTEN/PI3K/AKT pathway, reducing TSDR demethylation and FOXP3 and DNMT1 expression. Thus, CXCR4 targeting is a strategy to inhibit Tregs activity in the RCC tumour microenvironment.
Sections du résumé
BACKGROUND
BACKGROUND
Tregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in peripheral blood (PB)-Tregs isolated from primary RCC patients.
METHODS
METHODS
PB-Tregs were isolated from 77 RCC patients and 38 healthy donors (HDs). CFSE-T effector-Tregs suppression assay, IL-35, IFN-γ, IL-10, TGF-β1 secretion, and
RESULTS
RESULTS
R54 impaired PB-RCC-Tregs function, reduced
CONCLUSION
CONCLUSIONS
R54 impairs Tregs function in primary RCC patients targeting PTEN/PI3K/AKT pathway, reducing TSDR demethylation and FOXP3 and DNMT1 expression. Thus, CXCR4 targeting is a strategy to inhibit Tregs activity in the RCC tumour microenvironment.
Identifiants
pubmed: 38704478
doi: 10.1038/s41416-024-02702-x
pii: 10.1038/s41416-024-02702-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : IG-24746
Informations de copyright
© 2024. The Author(s).
Références
Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8:420–44.
pubmed: 34967848
doi: 10.1001/jamaoncol.2021.6987
Coombes M, Briggs K, Bone J, Clayman G, El-Naggar A, Dent S. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. Oncogene. 2003;22:8902–11.
pubmed: 14654786
doi: 10.1038/sj.onc.1207050
Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, et al. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Cancer Netw 2020;18:1160–70.
doi: 10.6004/jnccn.2020.0043
Feldman DR, Baum MS, Ginsberg MS, Hassoun H, Flombaum CD, Velasco S, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:1432–9.
pubmed: 19224847
pmcid: 3655420
doi: 10.1200/JCO.2008.19.0108
Kim IH, Lee HJ. The frontline immunotherapy-based treatment of advanced clear cell renal cell carcinoma: current evidence and clinical perspective. Biomedicines. 2022;10:251.
Diaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol. 2020;16:721–35.
pubmed: 32733094
doi: 10.1038/s41581-020-0316-3
Zhu G, Pei L, Yin H, Lin F, Li X, Zhu X, et al. Profiles of tumor-infiltrating immune cells in renal cell carcinoma and their clinical implications. Oncol Lett. 2019;18:5235–42.
pubmed: 31612034
pmcid: 6781756
Heidegger I, Pircher A, Pichler R. Targeting the tumor microenvironment in renal cell cancer biology and therapy. Front Oncol 2019;9:490.
pubmed: 31259150
pmcid: 6587703
doi: 10.3389/fonc.2019.00490
Lui PP, Cho I, Ali N. Tissue regulatory T cells. Immunology. 2020;161:4–17.
pubmed: 32463116
pmcid: 7450170
doi: 10.1111/imm.13208
Zhao H, Liao X, Kang Y. Tregs: Where we are and what comes next? Front Immunol. 2017;8:1578.
pubmed: 29225597
pmcid: 5705554
doi: 10.3389/fimmu.2017.01578
Allos H, Al Dulaijan BS, Choi J, Azzi J. Regulatory T cells for more targeted immunosuppressive therapies. Clin Lab Med. 2019;39:1–13.
pubmed: 30709499
doi: 10.1016/j.cll.2018.11.001
Wing JB, Tanaka A, Sakaguchi S. Human FOXP3. Immunity. 2019;50:302–16.
pubmed: 30784578
doi: 10.1016/j.immuni.2019.01.020
Kressler C, Gasparoni G, Nordström K, Hamo D, Salhab A, Dimitropoulos C, et al. Targeted de-methylation of the FOXP3-TSDR is sufficient to induce physiological FOXP3 expression but not a functional Treg Phenotype. Front Immunol. 2020;11:609891.
pubmed: 33488615
doi: 10.3389/fimmu.2020.609891
Khosravi M, Bidmeshkipour A, Cohen JL, Moravej A, Hojjat-Assari S, Naserian S, et al. Induction of CD4(+)CD25(+)FOXP3(+) regulatory T cells by mesenchymal stem cells is associated with modulation of ubiquitination factors and TSDR demethylation. Stem Cell Res Ther 2018;9:273.
pubmed: 30359308
pmcid: 6203284
doi: 10.1186/s13287-018-0991-1
Griffiths RW, Elkord E, Gilham DE, Ramani V, Clarke N, Stern PL, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007;56:1743–53.
pubmed: 17487490
pmcid: 11030591
doi: 10.1007/s00262-007-0318-z
Liotta F, Gacci M, Frosali F, Querci V, Vittori G, Lapini A, et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011;107:1500–6.
pubmed: 20735382
doi: 10.1111/j.1464-410X.2010.09555.x
Finke JH, Rini B, Ireland J, Rayman P, Richmond A, Golshayan A, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:6674–82.
doi: 10.1158/1078-0432.CCR-07-5212
Pan Q, Wang L, Chai S, Zhang H, Li B. The immune infiltration in clear cell Renal Cell Carcinoma and their clinical implications: A study based on TCGA and GEO databases. J Cancer. 2020;11:3207–15.
pubmed: 32231726
pmcid: 7097965
doi: 10.7150/jca.37285
Pompura, SL & Dominguez-Villar, M The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. J Leukoc Biol (2018) https://doi.org/10.1002/JLB.2MIR0817-349R .
Delgoffe GM, Woo SR, Turnis ME, Gravano DM, Guy C, Overacre AE, et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature. 2013;501:252–6.
pubmed: 23913274
pmcid: 3867145
doi: 10.1038/nature12428
Yan M, Jene N, Byrne D, Millar EK, O’Toole SA, McNeil CM, et al. Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011;13:R47.
pubmed: 21521526
pmcid: 3219210
doi: 10.1186/bcr2869
Mezzapelle R, Leo M, Caprioglio F, Colley LS, Lamarca A, Sabatino L, et al. CXCR4/CXCL12 Activities in the tumor microenvironment and implications for tumor immunotherapy. Cancers. 2022;14:2314.
Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71:5522–34.
pubmed: 21742774
pmcid: 3959864
doi: 10.1158/0008-5472.CAN-10-3143
Li B, Zeng Y, Reeves PM, Ran C, Liu Q, Qu X, et al. AMD3100 augments the efficacy of Mesothelin-targeted, immune-activating VIC-008 in Mesothelioma by modulating intratumoral immunosuppression. Cancer Immunol Res. 2018;6:539–51.
pubmed: 29511032
doi: 10.1158/2326-6066.CIR-17-0530
Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci USA. 2019;116:4558–66.
pubmed: 30700545
pmcid: 6410779
doi: 10.1073/pnas.1815515116
Zeng Y, Li B, Liang Y, Reeves PM, Qu X, Ran C, et al. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment. FASEB J. 2019;33:6596–608.
pubmed: 30802149
pmcid: 6463916
doi: 10.1096/fj.201802067RR
Portella L, Vitale R, De Luca S, D’Alterio C, Ieranò C, Napolitano M, et al. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One. 2013;8:e74548.
pubmed: 24058588
pmcid: 3772838
doi: 10.1371/journal.pone.0074548
Di Maro S, Trotta AM, Brancaccio D, Di Leva FS, La Pietra V, Ieranò C, et al. Exploring the N-terminal region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-stable cyclic peptides as novel, potent C-X-C Chemokine Receptor Type 4 (CXCR4) antagonists. J Med Chem. 2016;59:8369–80.
pubmed: 27571038
doi: 10.1021/acs.jmedchem.6b00695
Di Maro S, Di Leva FS, Trotta AM, Brancaccio D, Portella L, Aurilio M, et al. Structure-activity relationships and biological characterization of a novel, potent, and serum stable C-X-C Chemokine receptor Type 4 (CXCR4) antagonist. J Med Chem. 2017;60:9641–52.
pubmed: 29125295
doi: 10.1021/acs.jmedchem.7b01062
Santagata S, Napolitano M, D’Alterio C, Desicato S, Maro SD, Marinelli L, et al. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer. Oncotarget. 2017;8:77110–20.
pubmed: 29100374
pmcid: 5652768
doi: 10.18632/oncotarget.20363
Santagata S, Rea G, Castaldo D, Napolitano M, Capiluongo A, D’Alterio C, et al. Hepatocellular carcinoma (HCC) tumor microenvironment is more suppressive than colorectal cancer liver metastasis (CRLM) tumor microenvironment. Hepatol Int (2023). https://doi.org/10.1007/s12072-023-10537-6 .
Fritzsching B, Haas J, König F, Kunz P, Fritzsching E, Pöschl J, et al. Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLoS One. 2011;6:e17988.
pubmed: 21437244
pmcid: 3060879
doi: 10.1371/journal.pone.0017988
Haas J, Schopp L, Storch-Hagenlocher B, Fritzsching B, Jacobi C, Milkova L, et al. Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis. Blood. 2008;111:761–6.
pubmed: 17967942
doi: 10.1182/blood-2007-08-104877
Durr C, Pfeifer D, Claus R, Schmitt-Graeff A, Gerlach UV, Graeser R, et al. CXCL12 mediates immunosuppression in the lymphoma microenvironment after allogeneic transplantation of hematopoietic cells. Cancer Res. 2010;70:10170–81.
pubmed: 21159639
doi: 10.1158/0008-5472.CAN-10-1943
Liu HR, Li WM. Treg-specific demethylated region activity in isolated regulatory t lymphocytes is a surrogate for disease severity in hepatocellular carcinoma. IUBMB life. 2015;67:355–60.
pubmed: 25907075
doi: 10.1002/iub.1378
Rainbow DB, Yang X, Burren O, Pekalski ML, Smyth DJ, Klarqvist MD, et al. Epigenetic analysis of regulatory T cells using multiplex bisulfite sequencing. Eur J Immunol. 2015;45:3200–3.
pubmed: 26420295
pmcid: 4832369
doi: 10.1002/eji.201545646
Wegrzyn AS, Kedzierska AE, Obojski A. Identification and classification of distinct surface markers of T regulatory cells. Front Immunol. 2022;13:1055805.
pubmed: 36741366
doi: 10.3389/fimmu.2022.1055805
Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, et al. Interferon-γ drives T. Cell. 2017;169:1130–1141.e1111.
pubmed: 28552348
pmcid: 5509332
doi: 10.1016/j.cell.2017.05.005
Chuckran CA, Liu C, Bruno TC, Workman CJ, Vignali, DA. Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. J Immunother Cancer. 2020;8:e000967.
Toker A, Engelbert D, Garg G, Polansky JK, Floess S, Miyao T, et al. Active demethylation of the Foxp3 locus leads to the generation of stable regulatory T cells within the thymus. J Immunol. 2013;190:3180–8.
pubmed: 23420886
doi: 10.4049/jimmunol.1203473
Lu CH, Wu CJ, Chan CC, Nguyen DT, Lin KR, Lin SJ, et al. DNA Methyltransferase inhibitor promotes human CD4. Front Immunol. 2016;7:488.
pubmed: 27877174
pmcid: 5099256
doi: 10.3389/fimmu.2016.00488
Xin PL, Jie LF, Cheng Q, Bin DY, Dan CW. Pathogenesis and function of Interleukin-35 in Rheumatoid arthritis. Front Pharm. 2021;12:655114.
doi: 10.3389/fphar.2021.655114
Hao Y, Dong H, Li W, Lv X, Shi B, Gao P. The molecular role of IL-35 in non-small cell lung cancer. Front Oncol. 2022;12:874823.
pubmed: 35719927
pmcid: 9204334
doi: 10.3389/fonc.2022.874823
Turnis ME, Sawant DV, Szymczak-Workman AL, Andrews LP, Delgoffe GM, Yano H, et al. Interleukin-35 limits anti-tumor immunity. Immunity. 2016;44:316–29.
pubmed: 26872697
pmcid: 4758699
doi: 10.1016/j.immuni.2016.01.013
Dwivedi M, Tiwari S, Kemp EH, Begum R. Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. Heliyon. 2022;8:e10450.
pubmed: 36082331
pmcid: 9445387
doi: 10.1016/j.heliyon.2022.e10450
Schnell A, Bod L, Madi A, Kuchroo VK. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res. 2020;30:285–99.
pubmed: 31974523
pmcid: 7118128
doi: 10.1038/s41422-020-0277-x
Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381–405.
pubmed: 28431241
pmcid: 5546324
doi: 10.1016/j.cell.2017.04.001
Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell JC, et al. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol. 2004;172:5287–96.
pubmed: 15100267
doi: 10.4049/jimmunol.172.9.5287
Crellin NK, Garcia RV, Levings MK. Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood. 2007;109:2014–22.
pubmed: 17062729
doi: 10.1182/blood-2006-07-035279
Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med. 2008;205:565–74.
pubmed: 18283119
pmcid: 2275380
doi: 10.1084/jem.20071477
Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, et al. The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment. Sci Adv. 2015;1:e1500845.
pubmed: 26601142
pmcid: 4640592
doi: 10.1126/sciadv.1500845
Santinon F, Ezzahra BF, Bachais M, Sarabia Pacis A, Rudd CE. Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade. Sci Rep. 2022;12:18509.
pubmed: 36323740
pmcid: 9630443
doi: 10.1038/s41598-022-23016-z
Piro G, Carbone C, Carbognin L, Pilotto S, Ciccarese C, Iacovelli R, et al. Revising PTEN in the Era of immunotherapy: new perspectives for an old story. Cancers. 2019;11:1525.
Dixon ML, Leavenworth JD, Leavenworth JW. Lineage reprogramming of effector regulatory T cells in cancer. Front Immunol. 2021;12:717421.
pubmed: 34394124
pmcid: 8355732
doi: 10.3389/fimmu.2021.717421
Yan Y, Huang L, Liu Y, Yi M, Chu Q, Jiao D, et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol. 2022;15:104.
pubmed: 35948909
pmcid: 9364625
doi: 10.1186/s13045-022-01322-3
Huynh A, DuPage M, Priyadharshini B, Sage PT, Quiros J, Borges CM, et al. Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. Nat Immunol. 2015;16:188–96.
pubmed: 25559257
pmcid: 4297515
doi: 10.1038/ni.3077
Ouyang W, Liao W, Luo CT, Yin N, Huse M, Kim MV, et al. Novel Foxo1-dependent transcriptional programs control T(reg) cell function. Nature. 2012;491:554–9.
pubmed: 23135404
pmcid: 3771531
doi: 10.1038/nature11581
Ouyang W, Beckett O, Ma Q, Paik JH, DePinho RA, Li MO. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol. 2010;11:618–27.
pubmed: 20467422
doi: 10.1038/ni.1884
Kerdiles YM, Stone EL, Beisner DR, McGargill MA, Ch’en IL, Stockmann C, et al. Foxo transcription factors control regulatory T cell development and function. Immunity. 2010;33:890–904.
pubmed: 21167754
pmcid: 3034255
doi: 10.1016/j.immuni.2010.12.002
Wang L, Liu Y, Beier UH, Han R, Bhatti TR, Akimova T, et al. Foxp3+ T-regulatory cells require DNA methyltransferase 1 expression to prevent development of lethal autoimmunity. Blood. 2013;121:3631–9.
pubmed: 23444399
pmcid: 3643763
doi: 10.1182/blood-2012-08-451765
Xi Y, Qi Z, Ma J, Chen Y. PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells. Clin Exp Metastasis. 2020;37:173–85.
pubmed: 31571016
doi: 10.1007/s10585-019-09998-7
Ma J, Sun X, Wang Y, Chen B, Qian L. Fibroblast-derived CXCL12 regulates PTEN expression and is associated with the proliferation and invasion of colon cancer cells via PI3k/Akt signaling. Cell Commun Signal. 2019;17:119.
pubmed: 31500630
pmcid: 6734448
doi: 10.1186/s12964-019-0432-5
Zhang X, Jin B, Huang C. The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets. 2007;7:305–16.
pubmed: 17979625
doi: 10.2174/156800907780809741
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998;280:1614–7.
pubmed: 9616126
doi: 10.1126/science.280.5369.1614
Gong G, Lin T, Yuan Y. Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer. J Ovarian Res. 2020;13:30.
pubmed: 32192517
pmcid: 7082962
doi: 10.1186/s13048-020-00632-9
Nemenoff RA, Simpson PA, Furgeson SB, Kaplan-Albuquerque N, Crossno J, Garl PJ, et al. Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha. Circ Res. 2008;102:1036–45.
pubmed: 18340011
doi: 10.1161/CIRCRESAHA.107.169896
Nengroo MA, Khan MA, Verma A, Datta D. Demystifying the CXCR4 conundrum in cancer biology: Beyond the surface signaling paradigm. Biochim Biophys Acta Rev Cancer. 2022;1877:188790.
pubmed: 36058380
doi: 10.1016/j.bbcan.2022.188790
Sun R, Sun Y, Wu C, Liu Y, Zhou M, Dong Y, et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer. Mol Ther. 2023;31:3193–209.
pubmed: 37735875
doi: 10.1016/j.ymthe.2023.09.010
Hoefflin R, Harlander S, Schäfer S, Metzger P, Kuo F, Schönenberger D, et al. HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun. 2020;11:4111.
pubmed: 32807776
pmcid: 7431415
doi: 10.1038/s41467-020-17873-3